JP2019515899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515899A5 JP2019515899A5 JP2018553360A JP2018553360A JP2019515899A5 JP 2019515899 A5 JP2019515899 A5 JP 2019515899A5 JP 2018553360 A JP2018553360 A JP 2018553360A JP 2018553360 A JP2018553360 A JP 2018553360A JP 2019515899 A5 JP2019515899 A5 JP 2019515899A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- agent
- dose
- human subject
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 19
- 229940079593 drug Drugs 0.000 claims 19
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 210000001995 reticulocyte Anatomy 0.000 claims 6
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 5
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000037452 priming Effects 0.000 claims 5
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003978 infusion fluid Substances 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 238000012292 receptor occupancy assay Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022140214A JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2024023723A JP2024059764A (ja) | 2016-04-15 | 2024-02-20 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323330P | 2016-04-15 | 2016-04-15 | |
| US62/323,330 | 2016-04-15 | ||
| US201662427679P | 2016-11-29 | 2016-11-29 | |
| US62/427,679 | 2016-11-29 | ||
| PCT/US2017/027662 WO2017181033A1 (en) | 2016-04-15 | 2017-04-14 | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140214A Division JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515899A JP2019515899A (ja) | 2019-06-13 |
| JP2019515899A5 true JP2019515899A5 (OSRAM) | 2020-05-14 |
| JP7532009B2 JP7532009B2 (ja) | 2024-08-13 |
Family
ID=60042716
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553360A Active JP7532009B2 (ja) | 2016-04-15 | 2017-04-14 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2022140214A Active JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2024023723A Pending JP2024059764A (ja) | 2016-04-15 | 2024-02-20 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140214A Active JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2024023723A Pending JP2024059764A (ja) | 2016-04-15 | 2024-02-20 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11472878B2 (OSRAM) |
| EP (3) | EP3442578B1 (OSRAM) |
| JP (3) | JP7532009B2 (OSRAM) |
| KR (3) | KR20240016445A (OSRAM) |
| CN (3) | CN115350276A (OSRAM) |
| AU (2) | AU2017250809B2 (OSRAM) |
| CA (1) | CA3019676A1 (OSRAM) |
| ES (1) | ES2909835T3 (OSRAM) |
| PL (1) | PL3442578T3 (OSRAM) |
| PT (1) | PT3442578T (OSRAM) |
| SI (1) | SI3442578T1 (OSRAM) |
| WO (1) | WO2017181033A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CN111247172B (zh) | 2017-10-18 | 2023-11-14 | 四十七公司 | 基于抗cd47剂的卵巢癌疗法 |
| EP4129336B1 (en) | 2018-02-12 | 2025-05-07 | Forty Seven, LLC | Anti-cd47 agent-based treatment of cd20-positive cancer |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| WO2020009725A1 (en) * | 2018-07-05 | 2020-01-09 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| MY205933A (en) | 2018-09-27 | 2024-11-21 | Celgene Corp | Sirp-alpha binding proteins and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| PL3817773T3 (pl) | 2018-11-26 | 2024-10-28 | Forty Seven, Inc. | Humanizowane przeciwciała przeciwko c-kit |
| KR20210094609A (ko) | 2018-11-28 | 2021-07-29 | 포티 세븐, 인코포레이티드 | 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc |
| KR20220113353A (ko) | 2019-09-18 | 2022-08-12 | 람캅 바이오 알파 에이지 | Ceacam5 및 cd3에 대한 이중특이적 항체 |
| US11702474B2 (en) | 2019-12-17 | 2023-07-18 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
| US20230081265A1 (en) * | 2020-04-06 | 2023-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody formulation |
| WO2022076928A1 (en) * | 2020-10-09 | 2022-04-14 | Sana Biotechnology, Inc. | METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT |
| US12071481B2 (en) | 2020-12-23 | 2024-08-27 | D-10 Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| EP4274853A4 (en) * | 2021-01-05 | 2024-12-04 | National Institute Of Biological Sciences, Beijing | BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47 |
| WO2023002415A2 (en) * | 2021-07-20 | 2023-01-26 | Magenta Therapeutics, Inc. | Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3056515T4 (da) | 2008-01-15 | 2025-10-20 | Univ Leland Stanford Junior | Fremgangsmåde til at manipulere fagocytose medieret af cd47 |
| CA2714006A1 (en) * | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
| ES2616010T3 (es) * | 2010-05-14 | 2017-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anticuerpos monoclonales humanizados y quiméricos a CD47 |
| CN104136037B (zh) | 2012-01-17 | 2018-02-23 | 小利兰·斯坦福大学托管委员会 | 高亲和力SIRP‑α试剂 |
| HRP20191500T1 (hr) | 2012-02-06 | 2019-11-29 | Inhibrx Inc | Protutijela protiv cd47 i postupci njihove upotrebe |
| BR112015018851A2 (pt) | 2013-02-06 | 2017-07-18 | Inhibrx Llc | anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos |
| AU2014238105B2 (en) * | 2013-03-15 | 2018-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-CD47 agents |
| RU2015145610A (ru) | 2013-03-27 | 2017-05-04 | Дженентек, Инк. | Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина |
| ES2898627T3 (es) | 2013-04-29 | 2022-03-08 | Univ Leland Stanford Junior | Uso de agentes anti-CD47 para mejorar la inmunización |
| WO2015050983A1 (en) | 2013-10-01 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules |
| CN106456748A (zh) * | 2014-01-08 | 2017-02-22 | 小利兰·斯坦福大学托管委员会 | 小细胞肺癌的靶向疗法 |
| CN108025060A (zh) * | 2014-06-08 | 2018-05-11 | 瑞美德生物医药科技有限公司 | 使用胰高血糖素受体拮抗性抗体治疗1型糖尿病的方法 |
| WO2016028810A1 (en) * | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| EP3204420B1 (en) * | 2014-10-10 | 2020-09-02 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods to eliminate cancer stem cells by targeting cd47 |
| US20230081265A1 (en) * | 2020-04-06 | 2023-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody formulation |
-
2017
- 2017-04-14 US US16/089,115 patent/US11472878B2/en active Active
- 2017-04-14 EP EP17783254.0A patent/EP3442578B1/en active Active
- 2017-04-14 EP EP24159469.6A patent/EP4349412A3/en active Pending
- 2017-04-14 CA CA3019676A patent/CA3019676A1/en active Pending
- 2017-04-14 CN CN202210926503.6A patent/CN115350276A/zh active Pending
- 2017-04-14 WO PCT/US2017/027662 patent/WO2017181033A1/en not_active Ceased
- 2017-04-14 PT PT177832540T patent/PT3442578T/pt unknown
- 2017-04-14 SI SI201731120T patent/SI3442578T1/sl unknown
- 2017-04-14 AU AU2017250809A patent/AU2017250809B2/en active Active
- 2017-04-14 KR KR1020247002294A patent/KR20240016445A/ko active Pending
- 2017-04-14 JP JP2018553360A patent/JP7532009B2/ja active Active
- 2017-04-14 CN CN201780029157.9A patent/CN109152837A/zh active Pending
- 2017-04-14 EP EP22155479.3A patent/EP4074339A1/en active Pending
- 2017-04-14 KR KR1020237006777A patent/KR20230035435A/ko not_active Ceased
- 2017-04-14 PL PL17783254T patent/PL3442578T3/pl unknown
- 2017-04-14 CN CN202311544173.5A patent/CN117695387A/zh active Pending
- 2017-04-14 KR KR1020187032126A patent/KR102505253B1/ko active Active
- 2017-04-14 ES ES17783254T patent/ES2909835T3/es active Active
-
2022
- 2022-09-02 JP JP2022140214A patent/JP7442591B2/ja active Active
- 2022-09-08 US US17/930,621 patent/US11718670B2/en active Active
-
2023
- 2023-06-15 US US18/210,483 patent/US20230406923A1/en active Pending
-
2024
- 2024-02-20 JP JP2024023723A patent/JP2024059764A/ja active Pending
- 2024-05-22 AU AU2024203396A patent/AU2024203396A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515899A5 (OSRAM) | ||
| Theiss et al. | Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis | |
| JP2022166174A (ja) | 凝固第ｉｘ因子および／または活性化凝固第ｉｘ因子ならびに凝固第ｘ因子および／または活性化凝固第ｘ因子を認識する二重特異性抗体の使用法 | |
| JP2018515493A5 (OSRAM) | ||
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| JP2018535929A5 (OSRAM) | ||
| Qaiser et al. | Novel treatment pathways in pulmonary arterial hypertension | |
| Matsuda et al. | Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy | |
| ES3021882T3 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| CN106459971A (zh) | 用于治疗自身免疫性疾病的联合疗法 | |
| Patwardhan et al. | Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon | |
| EP2167038B1 (en) | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus | |
| Son et al. | SAMiRNA targeting amphiregulin alleviate total-body-irradiation-induced renal fibrosis | |
| JP2025148495A (ja) | Ｂ因子阻害剤の使用方法 | |
| JP2020510028A5 (OSRAM) | ||
| ES2935265T3 (es) | Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control | |
| CN116390756A (zh) | 抗前肌生成抑制蛋白/潜伏性肌生成抑制蛋白抗体用于治疗脊髓性肌萎缩的用途 | |
| JPWO2022240688A5 (OSRAM) | ||
| WO2019241742A1 (en) | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer | |
| RU2014110271A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Kumari et al. | Efficacy of therapeutic plasma exchange in a patient with coagulation inhibitors (acquired haemophilia A)–a case report | |
| CN112190708B (zh) | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 | |
| CN116685351A (zh) | Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究 | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| JPWO2020219960A5 (OSRAM) |